Men taking testosterone replacement therapy for age-related hypogonadism are at an increased risk for ischemic stroke, transient ischemic attack and myocardial infarction, especially during their first two years of use, researchers report in the American Journal of Medicine. 

Abbott Laboratories is planning to increase production of its lower-cost continuous glucose monitor, the FreeStyle Libre, by three to five times in the coming years, Reuters reported July 16.

Researchers at the University of Michigan have developed technology that flags stroke victims at the greatest risk for atrial fibrillation after an event, trumping standard methods of risk stratification to achieve greater accuracy.

A study published in the New England Journal of Medicine July 18 suggests it may be time for the medical community to rethink its perception of diastolic blood pressure, which has long been considered inferior to systolic BP as a measure of cardiovascular wellness.

High-sensitivity cardiac troponin I assays, when considered in the context of appropriate thresholds, can identify and expedite triage of patients at varying levels of risk for myocardial infarction, a JACC study found.

Massachusetts-based Azurity Pharmaceuticals announced July 10 it had received FDA approval for Katerzia Oral Suspension, making the drug the first and only FDA-approved amlodipine oral suspension to hit the commercial market.

A study of more than a quarter of a million heart patients in Canada has revealed statins are “significantly” underutilized to treat lipid abnormalities in individuals with and at risk for ASCVD.

A JACC: Cardiovascular Interventions study published this month suggests machine learning models are more predictive and discriminative than standard methods for identifying patients at the greatest risk of CV mortality and rehospitalization after PCI.

Methamphetamine abuse is on the rise among veterans with concomitant heart failure, according to a recent analysis published in the American Journal of Cardiology. 

Gadobutrol, sold by Bayer under the brand name Gadavist, became the first FDA-approved contrast agent for use in cardiac magnetic resonance imaging on July 15.